DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravir.

Author(s): Charpentier C, Roquebert B, Delelis O, Larrouy L, Matheron S, Tubiana R, Karmochkine M, Duval X, Chene G, Storto A, Collin G, Benard A, Damond F, Mouscadet JF, Brun-Vezinet F, Descamps D

Affiliation(s): Hopital Bichat-Claude Bernard, Laboratoire de Virologie, 46 Rue Henri Huchard, 75018 Paris, France. charlotte.charpentier@bch.aphp.fr

Publication date & source: 2011-03, Antimicrob Agents Chemother., 55(3):1293-5. Epub 2010 Dec 28.

Publication type: Research Support, Non-U.S. Gov't

We studied seven heavily pretreated HIV-2-infected patients exhibiting a virological failure while receiving a salvage raltegravir-containing regimen. At the time of virological failure, different resistance genetic pathways were observed: T97A-Y143C, Q148K, Q148R, G140S-Q148R, E92Q-Y143R-N155H, and T97A-N155H. Thus, despite a 40% difference in integrase genes between HIV-1 and HIV-2, the genetic pathways leading to raltegravir resistance are similar.

Page last updated: 2011-12-09

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017